https://www.selleckchem.com/pr....oducts/cct128930.htm
55 ng/ml; p = 0.0355). No differences were detected for the active MMP9. TIMP3 levels did not significantly differ between the AMD and control groups, nor between the different genotype groups for rs5754227. The results of our MMP9 analyses indicate that nAMD patients have on average higher systemic MMP9 levels than control individuals, and that this is partly driven by the rs142450006 variant near . This finding might be an interesting starting point for further exploration of MMP9 as a therapeutic target in nAMD, particularly among
Aimer
Commentaire
Partagez
